DK1499277T3 - PYY-36 til reduktion eller forebyggelse af obesitet - Google Patents

PYY-36 til reduktion eller forebyggelse af obesitet

Info

Publication number: DK1499277T3
Authority: DK; Denmark
Prior art keywords: pyy; reducing; preventing obesity; subject; decreasing
Prior art date: 2001-09-24

Application number

DK02768992T

Other languages

English (en)

Inventor

Michael Cowley

Roger Cone

Malcolm Low

Andrew Butler

Stephen R Bloom

Caroline J Small

Rachael L Batterham

Mohammad Ali Ghatei

Original Assignee

Imp Innovations Ltd

Univ Oregon Health & Science

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-24

Filing date

2002-09-24

Publication date

2009-05-11

2002-01-10 Priority claimed from GBGB0200507.2A external-priority patent/GB0200507D0/en

2002-09-24 Application filed by Imp Innovations Ltd, Univ Oregon Health & Science filed Critical Imp Innovations Ltd

2009-05-11 Application granted granted Critical

2009-05-11 Publication of DK1499277T3 publication Critical patent/DK1499277T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Zoology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Birds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Liquid Developers In Electrophotography (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Plural Heterocyclic Compounds (AREA)
Fats And Perfumes (AREA)
Oscillators With Electromechanical Resonators (AREA)
Lasers (AREA)
Toilet Supplies (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

DK02768992T 2001-09-24 2002-09-24 PYY-36 til reduktion eller forebyggelse af obesitet DK1499277T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32440601P	2001-09-24	2001-09-24
GBGB0200507.2A GB0200507D0 (en)	2002-01-10	2002-01-10	Appetite suppression
US39210902P	2002-06-28	2002-06-28
PCT/US2002/031944 WO2003026591A2 (en)	2001-09-24	2002-09-24	Modification of feeding behavior

Publications (1)

Publication Number	Publication Date
DK1499277T3 true DK1499277T3 (da)	2009-05-11

Family

ID=27256373

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02768992T DK1499277T3 (da)	2001-09-24	2002-09-24	PYY-36 til reduktion eller forebyggelse af obesitet

Country Status (19)

Country	Link
US (2)	US7459432B2 (da)
EP (2)	EP2050460A1 (da)
JP (3)	JP2005508324A (da)
KR (1)	KR100989647B1 (da)
CN (1)	CN100350968C (da)
AT (1)	ATE419863T1 (da)
AU (1)	AU2002332054B2 (da)
BR (1)	BR0212985A (da)
CA (1)	CA2461345A1 (da)
DE (1)	DE60230818D1 (da)
DK (1)	DK1499277T3 (da)
ES (1)	ES2320979T3 (da)
HK (1)	HK1070281A1 (da)
HU (1)	HU228621B1 (da)
IL (3)	IL160983A0 (da)
MX (1)	MXPA04002751A (da)
NZ (1)	NZ532427A (da)
PL (1)	PL205971B1 (da)
WO (1)	WO2003026591A2 (da)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7745216B2 (en)	1999-02-10	2010-06-29	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
JP2003518914A (ja)	1999-02-10	2003-06-17	キュリスインコーポレイテッド	グルコース代謝障害を治療する方法および試薬
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1349563B1 (en)	2000-12-14	2009-12-02	Amylin Pharmaceuticals, Inc.	Peptide pyy[3-36] for treatment of metabolic disorders
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
WO2003027637A2 (en)	2001-09-24	2003-04-03	Oregon Health And Science University	Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
US8058233B2 (en)	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
WO2004056314A2 (en) *	2002-12-17	2004-07-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) *	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7229966B2 (en) *	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) *	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CN1964630A (zh)	2003-02-13	2007-05-16	耶希瓦大学艾伯塔·爱恩斯坦医学院	通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US8008255B2 (en)	2003-05-30	2011-08-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for enhanced transmucosal delivery of peptides and proteins
CA2539548A1 (en)	2003-09-18	2005-03-31	Conforma Therapeutics Corporation	Novel heterocyclic compounds as hsp90-inhibitors
WO2005077072A2 (en)	2004-02-11	2005-08-25	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
EP2335716A3 (en) *	2004-02-11	2011-10-19	Amylin Pharmaceuticals Inc.	Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718671A2 (en) *	2004-02-23	2006-11-08	Rheoscience A/S	Peptide yy analogues
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
GB0411014D0 (en) *	2004-05-18	2004-06-23	Haptogen Ltd	Methods for the control treatment and management of obesity
US20070213270A1 (en) *	2004-06-16	2007-09-13	Costantino Henry R	Peptide yy formulations having increased stability and resistance to microbial agents
EP1791553B1 (en) *	2004-07-12	2013-10-23	Emisphere Technologies, Inc.	Compositions for delivering peptide yy and pyy agonists
US20060210655A1 (en) *	2004-10-07	2006-09-21	Martin Grigorov	Bioactive compositions, natural methods of producing them and computational methods for designing natural production processes
WO2006042242A2 (en)	2004-10-08	2006-04-20	Amylin Pharmaceuticals, Inc.	Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them
WO2006059106A2 (en)	2004-12-02	2006-06-08	Domantis Limited	Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
EP3000826A1 (en)	2004-12-13	2016-03-30	Amylin Pharmaceuticals, LLC	Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US8052996B2 (en)	2005-02-03	2011-11-08	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
PA8660701A1 (es) *	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
NZ561361A (en)	2005-02-11	2010-02-26	Amylin Pharmaceuticals Inc	GIP hybrid polypeptides with at least two hormonal activities
US20090286723A1 (en)	2005-02-11	2009-11-19	Amylin Pharmaceuticals, Inc.	Hybrid Polypeptides with Selectable Properties
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
GB0504857D0 (en)	2005-03-09	2005-04-13	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EP1934254A1 (en)	2005-09-21	2008-06-25	7TM Pharma A/S	Y4 selective receptor agonists for therapeutic interventions
US7851590B2 (en)	2005-09-21	2010-12-14	7Tm Pharma A/S	Y2 selective receptor agonists for therapeutic interventions
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
WO2007039318A2 (en) *	2005-10-06	2007-04-12	Bayer Schering Pharma Aktiengesellschaft	Neuropeptide y analogs
US20080255084A1 (en)	2005-10-21	2008-10-16	Randy Lee Webb	Combination of Organic Compounds
US20070232537A1 (en) *	2005-12-19	2007-10-04	Nastech Pharmaceutical Company Inc.	Intranasal pyy formulations with improved transmucosal pharmacokinetics
WO2007085887A1 (en) *	2006-01-27	2007-08-02	Pfizer Products Inc.	Pyy agonists and uses thereof
US8977517B2 (en) *	2006-06-05	2015-03-10	Creighton University	System and methods for evaluating efficacy of appetite-affecting drugs
GB0613196D0 (en)	2006-07-03	2006-08-09	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
PL2359808T3 (pl)	2006-08-09	2013-10-31	Intarcia Therapeutics Inc	Osmotyczne systemy dostawcze i zespoły tłokowe
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2946778A1 (en)	2006-09-22	2015-11-25	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
CA2682727C (en)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Indoledione derivative
IL290847B2 (en)	2007-04-23	2024-11-01	Intarcia Therapeutics Inc	Suspension formulations of insulinotropic peptides and their uses
JP5546451B2 (ja)	2007-06-04	2014-07-09	シナジーファーマシューティカルズインコーポレイテッド	胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7814038B1 (en) *	2007-12-06	2010-10-12	Dominic John Repici	Feedback-tolerant method and device producing weight-adjustment factors for pre-synaptic neurons in artificial neural networks
EP2247743B1 (en) *	2008-02-08	2016-04-06	Ambrx, Inc.	Modified leptin polypeptides and their uses
US8343140B2 (en) *	2008-02-13	2013-01-01	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102271509A (zh)	2008-10-31	2011-12-07	默沙东公司	用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010090876A2 (en)	2009-01-21	2010-08-12	University Of Florida Research Foundation, Inc.	Satiation peptide administration
US9260500B2 (en)	2009-07-02	2016-02-16	Takeda Pharmaceutical Company Limited	Peptide and use thereof
RU2753280C2 (ru)	2009-09-28	2021-08-12	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
CA2786314A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
PT2651398T (pt)	2010-12-16	2018-03-09	Novo Nordisk As	Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
GB201101459D0 (en) *	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103476258B (zh)	2011-02-25	2017-04-26	默沙东公司	用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
CA2834288A1 (en)	2011-04-25	2012-11-01	Advanced Bioscience Laboratories, Inc.	Truncated hiv envelope proteins (env), methods and compositions related thereto
ES2690553T3 (es)	2012-03-22	2018-11-21	Novo Nordisk A/S	Composiciones de péptidos GLP-1 y preparación de estas
US9456916B2 (en)	2013-03-12	2016-10-04	Medibotics Llc	Device for selectively reducing absorption of unhealthy food
CA2880901A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
RU2015140066A (ru)	2013-02-22	2017-03-30	Мерк Шарп И Доум Корп.	Противодиабетические бициклические соединения
US9011365B2 (en)	2013-03-12	2015-04-21	Medibotics Llc	Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en)	2013-03-12	2015-06-30	Medibotics Llc	Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
EP2970119B1 (en)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
DK2983690T3 (da) *	2013-04-10	2019-05-20	Univ Copenhagen	Neuropeptid Y-afledte peptider
WO2014178018A1 (en) *	2013-05-02	2014-11-06	Glaxosmithkline Intellectual Property Development Limited	Therapeutic peptides
US9549909B2 (en)	2013-05-03	2017-01-24	The Katholieke Universiteit Leuven	Method for the treatment of dravet syndrome
EP4424697A2 (en)	2013-06-05	2024-09-04	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
JP6629198B2 (ja)	2013-11-15	2020-01-15	ノヴォノルディスクアー／エス	３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
SI3068421T1 (sl)	2013-11-15	2019-08-30	Novo Nordisk A/S	Selektivne spojine PYY in njihova uporaba
US20170137486A1 (en)	2014-05-23	2017-05-18	Imperial Innovations Limited	Peptide yy (pyy) analogues
WO2016030534A1 (en)	2014-08-29	2016-03-03	Tes Pharma S.R.L.	INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN107920884B (zh)	2015-06-03	2021-08-27	因塔西亚制药公司	植入物放置和移除系统
EP3307768A1 (en)	2015-06-12	2018-04-18	Novo Nordisk A/S	Selective pyy compounds and uses thereof
KR101604212B1 (ko) *	2015-07-17	2016-03-17	울산대학교 산학협력단	Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
US20170174614A1 (en)	2015-12-22	2017-06-22	Zogenix International Limited	Metabolism resistant fenfluramine analogs and methods of using the same
CA3007286A1 (en)	2015-12-22	2017-06-29	Zogenix International Limited	Fenfluramine compositions and methods of preparing the same
US11311633B2 (en)	2016-04-16	2022-04-26	University Of Florida Research Foundation, Incorporated	Satiation peptides for weight loss and altered taste sensitivity
WO2017200943A1 (en)	2016-05-16	2017-11-23	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
MX2019001799A (es)	2016-08-24	2019-06-13	Zogenix International Ltd	Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
US10968232B2 (en)	2016-12-20	2021-04-06	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
WO2018129058A1 (en)	2017-01-03	2018-07-12	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3625247A4 (en) *	2017-05-16	2021-03-24	The University of Chicago	COMPOSITIONS AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF PATHOGENIC FUNGAL INFECTION AND FOR MAINTENANCE OF COMMENSALISM OF THE MICROBIOME
US10682317B2 (en)	2017-09-26	2020-06-16	Zogenix International Limited	Ketogenic diet compatible fenfluramine formulation
GB201720188D0 (en)	2017-12-04	2018-01-17	Imperial Innovations Ltd	Analogues of PYY
AU2019211322A1 (en)	2018-01-23	2020-07-23	Gila Therapeutics, Inc.	Peptide YY pharmaceutical formulations, compositions, and methods
SG11202006595RA (en)	2018-02-02	2020-08-28	Novo Nordisk As	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
GB2573145A (en) *	2018-04-26	2019-10-30	Univ Ulster	Peptides for metabolic disease
WO2019216919A1 (en)	2018-05-11	2019-11-14	Zogenix International Limited	Compositions and methods for treating seizure-induced sudden death
CN113302189A (zh)	2018-11-20	2021-08-24	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US11612574B2 (en)	2020-07-17	2023-03-28	Zogenix International Limited	Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN113092427A (zh) *	2021-04-02	2021-07-09	南京中医药大学	异硫氰酸荧光素在标记β内啡肽中的应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4175122A (en)	1975-04-15	1979-11-20	Burroughs Wellcome Co.	Biologically active amides
US4223017A (en)	1975-04-15	1980-09-16	Burroughs Wellcome Co.	Biologically active amides
GB1560933A (en)	1975-04-15	1980-02-13	Wellcome Found	Biologically activy polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4220653A (en) *	1979-01-24	1980-09-02	Vivino A Earl	Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4229389A (en)	1979-03-16	1980-10-21	Thompson Marine Corporation	Gas diffuser, aerator, or sparger apparatus
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja)	1983-06-29	1985-01-16	Dai Ichi Seiyaku Co Ltd	リポソ−ムの製造方法
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) *	1983-09-26	1991-02-21	Udo Dr Med Ehrenfeld	Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4701441A (en)	1985-02-11	1987-10-20	University Of Florida	Methods and compositions for stimulation of appetite
US4698327A (en) *	1985-04-25	1987-10-06	Eli Lilly And Company	Novel glycopeptide derivatives
CA1257199A (en)	1986-05-20	1989-07-11	Paul Y. Wang	Preparation containing bioactive macromolecular substance for multi-months release in vivo
HU196755B (en)	1986-09-16	1989-01-30	Gyogyszerkutato Intezet	Process for production of new substituated amilid derivatives and medical compositions containing them
IE63869B1 (en)	1986-11-06	1995-06-14	Res Dev Foundation	Aerosols containing liposomes and method for their preparation
JP2887325B2 (ja)	1988-06-28	1999-04-26	ラホヤキャンサーリサーチファウンデーション	デコリンによる細胞増殖の抑制
US5026685A (en)	1988-07-15	1991-06-25	The Salk Institute For Biological Studies	NPY peptide analogs
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
DE68925966T2 (de)	1988-12-22	1996-08-29	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (sv)	1990-06-28	1991-12-29	Perstorp Ab	Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5571695A (en)	1991-11-06	1996-11-05	Garvan Institute Of Medical Research	Human neuropeptide Y-Y1 receptor
DK39892D0 (da)	1992-03-25	1992-03-25	Bernard Thorens	Peptid
EP0619332B1 (en)	1992-10-28	1998-02-25	Kuraray Co., Ltd.	Polyurethane and leatherlike sheet made therefrom
JP2961045B2 (ja) *	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
PL310897A1 (en)	1993-03-29	1996-01-08	Univ Cincinnati	Analogues of yy peptide and their application
WO1995000162A1 (en)	1993-06-21	1995-01-05	Enzon, Inc.	Site specific synthesis of conjugated peptides
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
US5880131A (en)	1993-10-20	1999-03-09	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5965566A (en)	1993-10-20	1999-10-12	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5545549A (en)	1994-02-03	1996-08-13	Synaptic Pharmaceutical Corporation	DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5696093A (en)	1994-10-28	1997-12-09	Crc For Biopharmaceutical Research Pty Limited	Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
WO1996014336A1 (fr)	1994-11-07	1996-05-17	Kyowa Hakko Kogyo Co., Ltd.	Nouvelle oxyntomoduline
US6001970A (en)	1994-11-07	1999-12-14	Merck & Co., Inc	Modified human neuropeptide Y1 Receptors
US5574010A (en)	1994-11-14	1996-11-12	The Regents Of The University Of California	Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en)	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) *	1994-12-02	1999-11-23	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5907030A (en)	1995-01-25	1999-05-25	University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
US5912227A (en)	1995-01-27	1999-06-15	North Carolina State University	Method of enhancing nutrient uptake
US6558708B1 (en) *	1995-05-17	2003-05-06	Cedars-Sinai Medical Center	Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5635503A (en)	1995-06-07	1997-06-03	Bristol-Myers Squibb Company	Dihydropyridine npy antagonists: piperazine derivatives
US5668151A (en)	1995-06-07	1997-09-16	Bristol-Myers Squibb Company	Dihydropyridine NPY antagonists: piperidine derivatives
AU1328197A (en)	1995-12-01	1997-06-19	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
BR9707336B1 (pt)	1996-02-02	2009-01-13		dispositivo de embebição de fluido adequado para dosagem de leuprolida em um ambiente fluido de uso.
US5962270A (en)	1996-02-06	1999-10-05	Bionebraska, Inc.	Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5965392A (en)	1996-04-08	1999-10-12	Bayer Corporation	Neuropeptide Y receptor Y5 and nucleic acid sequences
US5919901A (en) *	1996-04-08	1999-07-06	Bayer Corporation	Neuropeptide Y receptor Y5 and nucleic acid sequences
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
AUPO029096A0 (en)	1996-06-05	1996-07-04	Crc For Biopharmaceutical Research Pty Ltd	Npy y2 agonists
US6355478B1 (en)	1996-06-17	2002-03-12	Eli Lilly And Company	Rhesus monkey neuropeptide Y Y2 receptor
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
CN1271086C (zh)	1996-08-30	2006-08-23	诺沃挪第克公司	Glp－1衍生物
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE366584T1 (de)	1996-11-12	2007-08-15	Novo Nordisk As	Verwendung von glp-1 peptiden
JP2000505105A (ja)	1996-11-13	2000-04-25	ユニヴァーシティ・オブ・シンシナティ	ペプチドｙｙのアナログおよびその使用
WO1998030231A1 (en) *	1997-01-07	1998-07-16	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the reduction of food intake
AU5773798A (en)	1997-01-29	1998-08-18	Polymasc Pharmaceuticals Plc	Pegylation process
US6048900A (en)	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6001836A (en)	1997-05-28	1999-12-14	Bristol-Myers Squibb Company	Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en)	1997-06-26	1999-03-30	Bristol-Myers Squibb Company	Dihydropyrimidone derivatives as NPY antagonists
US6093692A (en)	1997-09-25	2000-07-25	The University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
EP0920864A1 (en)	1997-12-03	1999-06-09	Pfizer Products Inc.	Combination therapy including a specific beta-3 agonist and an anorectic agent
EP2433623A1 (en) *	1998-02-02	2012-03-28	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
FR2774674B1 (fr)	1998-02-10	2000-03-24	Atochem Elf Sa	Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
DE69942307D1 (de)	1998-02-27	2010-06-10	Novo Nordisk As	N-terminal veränderte glp-1 abkömmlinge
US6046167A (en)	1998-03-25	2000-04-04	University Of Cincinnati	Peptide YY analogs
FR2777283B1 (fr)	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5993414A (en)	1998-04-23	1999-11-30	Medtronic, Inc.	Implantable device
NZ507763A (en)	1998-04-29	2003-06-30	Ortho Mcneil Pharm Inc	N-substituted aminotetralin sulphonamide derivatives useful as ligands for the neuropeptide Y Y5 receptor used in the treatment of obesity and other disorders
CA2346363A1 (en)	1998-10-07	2000-04-13	Ortho-Mcneil Pharmaceutical, Inc.	N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
TWI242000B (en)	1998-12-10	2005-10-21	Univ Southern California	Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
JP2002534512A (ja)	1999-01-15	2002-10-15	ノボノルディスクアクティーゼルスカブ	非ペプチドｇｌｐ−１アゴニスト
JP2003518914A (ja) *	1999-02-10	2003-06-17	キュリスインコーポレイテッド	グルコース代謝障害を治療する方法および試薬
US6407120B1 (en)	1999-02-18	2002-06-18	Pfizer Inc.	Neuropeptide Y antagonists
CA2369549A1 (en)	1999-04-02	2000-10-12	Robert W. Desimone	Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6218408B1 (en)	1999-06-30	2001-04-17	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (bicyclics)
US6340683B1 (en)	1999-04-22	2002-01-22	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (triazines)
AU4659200A (en)	1999-05-05	2000-11-21	Ortho-Mcneil Pharmaceutical, Inc.	3a,4,5,9b-tetrahydro-1h-benz(e)indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
US7601691B2 (en) *	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
ATE372782T1 (de)	1999-06-21	2007-09-15	Lilly Co Eli	Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
US6225330B1 (en)	1999-06-30	2001-05-01	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (tricyclics)
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6399631B1 (en)	1999-07-23	2002-06-04	Pfizer Inc.	Carbazole neuropeptide Y5 antagonists
EP1493742A1 (en)	1999-07-28	2005-01-05	Ortho-Mcneil Pharmaceutical, Inc.	Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
EP1207161B1 (en)	1999-08-25	2006-01-18	Banyu Pharmaceutical Co., Ltd.	Novel isoindole derivatives
CA2381111A1 (en)	1999-08-26	2001-03-01	Leah M. Giupponi	Npy antagonists: spiroisoquinolinone derivatives
WO2001014368A1 (en)	1999-08-26	2001-03-01	Viropharma Incorporated	Compounds, compositions and methods for treating influenza
CA2379585C (en)	1999-09-30	2006-06-20	James W. Darrow	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
EP1239871A1 (en)	1999-11-12	2002-09-18	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
US6436091B1 (en)	1999-11-16	2002-08-20	Microsolutions, Inc.	Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
CN101898982B (zh) *	1999-11-26	2012-07-04	盐野义制药株式会社	Npy y5拮抗剂
ES2227115T5 (es)	2000-01-10	2014-10-30	Amylin Pharmaceuticals, Inc.	Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
AU2001237254A1 (en)	2000-03-08	2001-09-17	Novo-Nordisk A/S	Lowering serum lipids
AU2001254686A1 (en)	2000-03-16	2001-09-24	Bayer Aktiengesellschaft	Regulation of human neuropeptide y-like g protein-coupled receptor
IL142707A0 (en) *	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
US6444675B2 (en)	2000-05-10	2002-09-03	Bristol-Myers Squibb Company	4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en)	2000-05-10	2002-08-13	Bristol-Myers Squibb Company	Squarate derivatives of dihydropyridine NPY antagonists
WO2001087335A2 (en)	2000-05-17	2001-11-22	Eli Lilly And Company	Method for selectively inhibiting ghrelin action
US6256216B1 (en) *	2000-05-18	2001-07-03	Integrated Device Technology, Inc.	Cam array with minimum cell size
US6391881B2 (en)	2000-05-19	2002-05-21	Bristol-Myers Squibb Company	Thiourea derivatives of dihydropyridine NPY antagonists
CA2407784C (en)	2000-05-19	2014-08-26	Bionebraska, Inc.	Treatment of acute coronary syndrome with glp-1
CN101301294A (zh)	2000-07-06	2008-11-12	症变治疗公司	Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
US6420352B1 (en)	2000-07-19	2002-07-16	W. Roy Knowles	Hair loss prevention
US6586403B1 (en) *	2000-07-20	2003-07-01	Salpep Biotechnology, Inc.	Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6900226B2 (en) *	2000-09-06	2005-05-31	Hoffman-La Roche Inc.	Neuropeptide Y antagonists
US20020156010A1 (en) *	2000-11-20	2002-10-24	Lustig Robert H.	Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
EP1349563B1 (en) *	2000-12-14	2009-12-02	Amylin Pharmaceuticals, Inc.	Peptide pyy[3-36] for treatment of metabolic disorders
WO2002066479A1 (fr)	2001-02-23	2002-08-29	Banyu Pharmaceutical Co.,Ltd.	Derives de l'isoindole
WO2002067918A1 (fr)	2001-02-27	2002-09-06	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de diallylmethylamine
JP2005500338A (ja) *	2001-07-26	2005-01-06	シェーリング　コーポレイション	置換尿素神経ペプチドｙｙ５レセプターアンタゴニスト
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
EP2329839B1 (en)	2002-01-10	2015-09-16	Imperial Innovations Limited	Modification of feeding behavior by GLP-1 and PYY
US8058233B2 (en) *	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US7166575B2 (en) *	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
ES2512499T3 (es) *	2003-04-08	2014-10-24	Yeda Research And Development Co., Ltd.	Fármacos pegilados reversibles
CN1220702C (zh)	2003-07-30	2005-09-28	北京中科亚光生物科技有限公司	促胰岛素分泌肽及其用途
WO2005035761A1 (en)	2003-10-16	2005-04-21	Compugen Ltd.	Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR20070039911A (ko)	2004-06-01	2007-04-13	도만티스 리미티드	증강된 혈청 반감기를 가지는 이특이성 융합 항체
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
GB0504857D0 (en)	2005-03-09	2005-04-13	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
KR101349808B1 (ko)	2005-06-13	2014-02-13	임페리얼 이노베이션스 리미티드	섭취행동에 관한 신규 화합물들 및 이들의 효능
WO2007056362A2 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
CA2638800A1 (en)	2006-02-22	2007-09-07	Merck & Co., Inc.	Oxyntomodulin derivatives
CA2654055A1 (en)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
GB0613196D0 (en)	2006-07-03	2006-08-09	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響

2002
- 2002-09-24 CN CNB028185846A patent/CN100350968C/zh not_active Expired - Fee Related
- 2002-09-24 KR KR1020097023184A patent/KR100989647B1/ko not_active IP Right Cessation
- 2002-09-24 MX MXPA04002751A patent/MXPA04002751A/es active IP Right Grant
- 2002-09-24 AT AT02768992T patent/ATE419863T1/de not_active IP Right Cessation
- 2002-09-24 HU HU0600337A patent/HU228621B1/hu not_active IP Right Cessation
- 2002-09-24 JP JP2003530230A patent/JP2005508324A/ja active Pending
- 2002-09-24 DK DK02768992T patent/DK1499277T3/da active
- 2002-09-24 DE DE60230818T patent/DE60230818D1/de not_active Expired - Lifetime
- 2002-09-24 US US10/490,776 patent/US7459432B2/en not_active Expired - Fee Related
- 2002-09-24 NZ NZ532427A patent/NZ532427A/en not_active IP Right Cessation
- 2002-09-24 ES ES02768992T patent/ES2320979T3/es not_active Expired - Lifetime
- 2002-09-24 BR BR0212985-0A patent/BR0212985A/pt not_active Application Discontinuation
- 2002-09-24 CA CA002461345A patent/CA2461345A1/en not_active Abandoned
- 2002-09-24 EP EP20080022583 patent/EP2050460A1/en not_active Withdrawn
- 2002-09-24 IL IL16098302A patent/IL160983A0/xx unknown
- 2002-09-24 PL PL374270A patent/PL205971B1/pl not_active IP Right Cessation
- 2002-09-24 EP EP02768992A patent/EP1499277B1/en not_active Expired - Lifetime
- 2002-09-24 AU AU2002332054A patent/AU2002332054B2/en not_active Ceased
- 2002-09-24 WO PCT/US2002/031944 patent/WO2003026591A2/en active Application Filing
2004
- 2004-03-21 IL IL160983A patent/IL160983A/en not_active IP Right Cessation
2005
- 2005-04-08 HK HK05103004.3A patent/HK1070281A1/xx not_active IP Right Cessation
2008
- 2008-08-29 US US12/202,197 patent/US8217001B2/en not_active Expired - Fee Related
2009
- 2009-06-15 IL IL199364A patent/IL199364A/en not_active IP Right Cessation
2010
- 2010-01-08 JP JP2010003242A patent/JP2010111694A/ja active Pending
2012
- 2012-11-29 JP JP2012260485A patent/JP6124565B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HUP0600337A3 (en)	2011-03-28
IL199364A0 (en)	2011-07-31
JP2013047275A (ja)	2013-03-07
EP1499277B1 (en)	2009-01-07
IL160983A (en)	2010-11-30
ES2320979T3 (es)	2009-06-01
CN1596119A (zh)	2005-03-16
WO2003026591A2 (en)	2003-04-03
EP1499277A4 (en)	2005-08-31
WO2003026591A3 (en)	2004-10-28
JP2010111694A (ja)	2010-05-20
JP6124565B2 (ja)	2017-05-10
DE60230818D1 (de)	2009-02-26
CA2461345A1 (en)	2003-04-03
HU228621B1 (en)	2013-04-29
BR0212985A (pt)	2005-08-30
EP2050460A1 (en)	2009-04-22
MXPA04002751A (es)	2005-09-08
EP1499277A2 (en)	2005-01-26
US20090209461A1 (en)	2009-08-20
AU2002332054B2 (en)	2007-11-08
KR20090122497A (ko)	2009-11-30
IL199364A (en)	2012-02-29
IL160983A0 (en)	2004-08-31
HK1070281A1 (en)	2005-06-17
US8217001B2 (en)	2012-07-10
ATE419863T1 (de)	2009-01-15
PL374270A1 (en)	2005-10-03
KR100989647B1 (ko)	2010-10-26
WO2003026591A9 (en)	2004-07-08
PL205971B1 (pl)	2010-06-30
JP2005508324A (ja)	2005-03-31
US7459432B2 (en)	2008-12-02
HUP0600337A2 (en)	2006-08-28
NZ532427A (en)	2008-07-31
CN100350968C (zh)	2007-11-28
US20050176630A1 (en)	2005-08-11

Publication	Publication Date	Title
DK1499277T3 (da)	2009-05-11	PYY-36 til reduktion eller forebyggelse af obesitet
WO2003057235A3 (en)	2003-12-11	Modification of feeding behavior
DK1377280T3 (da)	2007-10-08	Fyldmidler som mæthedsfornemmelsesgivende midler
IS7814A (is)	2005-04-20	Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
EP1481684A4 (en)	2008-04-02	REMEDIES FOR LIVER DISEASES, HYPERLIPEMIA AND DIABETES
DE50209912D1 (de)	2007-05-24	Turbokompressor mit verstellbaren Leitschaufeln
AU2003252182A8 (en)	2004-02-16	Therapeutic treatment for the metabolic syndrome and type 2 diabetes
ITMI20030095A1 (it)	2003-08-01	Procedimento e dispositivo per comandare o regolare un compressore.
FIU20020303U0 (fi)	2002-06-26	Potkuri säädettävällä nousulla
AU2003289925A1 (en)	2004-06-23	Copolymers based on n-vinylamide as adjuvants and agents for using in the agrotechnical field
EP1495039A4 (en)	2006-07-26	MUTANTS OF NEISSERIA, LIPOOLIGOSACCHARIDES AND IMMUNOGENIC COMPOSITIONS
ZA200703762B (en)	2008-09-25	Mutant porcine reproductive and respiratory syndrome virus
ATE341297T1 (de)	2006-10-15	Orthopädische schiene
ITRM20030485A0 (it)	2003-10-22	Composizione a base di citicolina in associazione con vitamine per laprevenzione ed il trattamento di patolgie oculari.
ITMI20030786A1 (it)	2003-10-19	Dispositivo di guida e di serraggio.
NO20052752D0 (no)	2005-06-07	Oromukosalpreparat og fremgangsmate for fremstilling derav.
BR0300829B1 (pt)	2011-10-04	carburador.
Campbell	2002	Wang Ruoxu (1174-1243) and his" talks on poetry"
DRYAS	2002	DEGLACIATION AND THE
ITMO20020003V0 (it)	2002-01-30	Cartolina interattiva perfezionata.
SE0203563D0 (sv)	2002-12-03	Natrumedel med smärtlindrande egenskap
ITMI20031817A1 (it)	2005-03-24	Dispositivo per la cottura di vivande in genere, particolarmente per camini, griglie e simili.
NO20030825D0 (no)	2003-02-21	Anordning og fremgangsmåte for innstilling av kurvatur på ryggdelene for stol
ITRM20030172A1 (it)	2003-10-18	Carburatore.
ITRM990235V0 (it)	1999-11-10	Dispositivo a bacchette per l'assunzione di cibi, in particolare riso.